Study of How Cancer Treatments Affect Fertility in Adolescents and Adults Aged 14 to 50

What this Trial Is About

Researchers are studying how cancer treatments that can harm reproductive cells, such as chemotherapy, radiotherapy, and immunotherapy, affect fertility in people with cancer. The study focuses on whether these treatments reduce the level of Anti-Mllerian hormone AMH, which reflects ovarian reserve in females, and sperm concentration, which relates to sperm quality in males. This international observational study involves fertility centers in Switzerland, Germany, Austria, and other interested centers worldwide, gathering data mostly from routine clinical care. Data collection occurs before the start of gonadotoxic cancer treatments and continues after treatment ends. The follow-up periods after treatment include assessments at 12 to 15 months, 5 years, and 10 years. The study collects blood samples to analyze hormone levels and sperm samples for males to assess fertility status. Additional evaluations include satisfaction with fertility preservation counseling, quality of life questionnaires, and tracking pregnancies and children born naturally or with fertility preservation assistance. Participants provide routine clinical data that doctors enter into a secure registry, with each center accessing only its own data. The research team monitors changes in AMH levels for females and sperm concentration for males at the specified follow-up times. They also assess participant satisfaction, quality of life, and pregnancy outcomes. This long-term observational study spans up to 15 years of data collection, aiming to better understand fertility impacts of cancer therapies over time.

Impact of Gonadotoxic Therapies on Fertility